Feeling unsure about the prospect of restrictions easing over the next couple of months? Here’s how to use the lockdown roadmap to prepare yourself for the return to “normality”. This week marks the first step in Boris Johnson’s ‘roadmap’ plan…
Read More
We asked an expert to explain what causes Sunday night anxiety
Written by Lauren Geall Welcome to Sleepless Nights, Stylist’s weekly series designed to help you put your Sunday night anxiety and worries to bed. This week, we’re exploring what causes Sunday night anxiety – and whether working from home has…
Read More
A Simple Phone Call Can Help Relieve Anxiety and Depression for Those in Lockdown
A new study recently published in JAMA Psychiatry found that a layperson-delivered phone call program could reduce feelings of loneliness, depression, and anxiety. These calls also improved the general mental health of study participants within 4 weeks. Each caller contacted…
Read More
UNH receives $2.97 million in grants to investigate the effectiveness of wilderness therapy
The University of New Hampshire’s Outdoor Behavioral Healthcare Center receives $2.97 million in grants to conduct a first-of-its-kind randomized study looking at the effectiveness of outdoor behavioral health (OBH), or wilderness therapy, a prescriptive treatment for teens struggling with depression,…
Read More
Rixadone Oral
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. RIXADONE Risperidone Oral solution 1mg/mL Consumer Medicine Information What is in this leaflet Please read this leaflet carefully before you start taking Rixadone. This leaflet answers some…
Read More
APOTEX-Pantoprazole
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APOTEX- PANTOPRAZOLE TABLETS Contains the active ingredient, pantoprazole (as sodium sesquihydrate) Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about pantoprazole….
Read More
Buvidal Monthly
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. BUVIDAL® Buprenorphine Consumer Medicine Information Warning: Risk of Serious Harm or Death with Intravenous Administration Serious harm or death could result if administered intravenously. Buvidal Monthly forms…
Read More
APO-Amisulpride
NOTICE: This Consumer Medicine Information (CMI) is intended for persons living in Australia. APO-AMISULPRIDE Amisulpride Consumer Medicine Information What is in this leaflet This leaflet answers some common questions about amisulpride. It does not contain all the available information. It…
Read More